{
  "pmcid": "11620001",
  "sha256": "de06ed5b008f4840f6b14af78b305eaf5f28494d13eb464f26e437cbba527e12",
  "timestamp_utc": "2025-11-09T23:18:18.360780+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.259151177199506,
    "reading_ease": 33.788321974390755,
    "word_count": 269
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of External Stenting in Saphenous Vein Graft Failure Prevention"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to receive either external stenting or standard care."
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligibility criteria included adults with multivessel coronary artery disease."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either external stenting or standard care."
      },
      "Objective": {
        "score": 1,
        "evidence": "To assess the effect of external stenting on SVG failure rates."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was SVG failure at 12 months, defined as >50% stenosis on angiography."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed using sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was applied to outcome assessors, patients, and clinicians."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 100 to the intervention group and 100 to the control group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 98 participants in the intervention group and 97 in the control group using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group showed a significant reduction in SVG failure (mean difference = 10%, 95% CI 5% to 15%; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were reported in 3% of the intervention group and 1% of the control group, with mild severity."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT12345678."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by the National Institutes of Health."
      }
    },
    "total_score": 24,
    "max_score": 25
  }
}